B. PHARM. EIGHTH SEMESTER PHARMACEUTICAL REGULATORY SCIENCE BP804ET [USE OMR SHEET FOR OBJECTIVE PART]



Duration: 3 hrs.			Full Marks: 75					
Tim	(PART-A: Objective) Time: 30 min. Marks: 20							
Che	oose the correct answer from	the following:	1×20=20					
1.	List of approved drugs and their associa a. Pink book c. Red book	ated IPR is available in b. Orange book d. Indian pharmacopoe	ia					
2.	Identify the relevant regulatory body in a. BLA c. CBER	USFDA for approval of drug b. IND d. CDER	s					
3.	Rule 96 means- a. Manner of packaging c. Manner of labelling	b. Manner of importingd. Manner of distribution						
4.	How many types of DMF are therea. 5 c. 2	b. 3 d. 4						
5.	Placebo means- a. New medicine c. Medically ineffectual treatment	b. Medically effectual tod. Clinical study	reatment					
6.	Drug regulatory body of Brazil is- a. TGA c. MHLW	b. SFDA d. ANVISA						
7.	Which regulatory body reviews and upon. WHO c. IPC	dates the Indian pharmacopo b. CDSCO d. DTAB	eia.					
8.	The Clinical trial legislative requiremen a. Schedule Y c. Schedule C	ts are guided under- b. Schedule T d. Schedule X						
9.	On, the CTD became the mand a. June 2003 c. July 2003	datory format for NDA in the b. January 2003 d. July 2013	EU and Japan.					
10.	Comparative trial is also known as- a. Three arm head-to-head study c. Two arm head-to-head study.	b. Placebod. Phase I clinical study						

11.	IRB means a. Institutional review board c. Indian review board		Independent review board International review board	
12.	Type I DMF deals with - a. Packaging materials c. Drug substance		Manufacturing site Excipients	
13.	Who reviews, evaluates and approves the s	tific and ethical aspects of a clinical		
	trial a. ICH c. IPC		CPCSEA IRB/IEC	
14.	The CFR is divided into -			
	a. 40 titles		25 titles	
	c. 50 titles		10 titles	
15.	Narcotic and psychotropic substances Act a. 1985			
	a. 1985 c. 1954		1986 1956	
16.	Informed consent form is also known as-	u.	1930	
10.	a. Informed consent document	b	Patient consent form	
	c. Both (a) and (b)		None of the above	
17.				
	a. CTD		eCTD	
	c. DMF	d.	ACTD	
18.	Which schedule specifies the general requimaterials-	reme	ents for factory premises and	
	a. Schedule Y		Schedule G	
	c. Schedule T	d.	Schedule M	
19.	MHLW is a regulatory body of -			
	a. India		Europe	
	c. Japan	d.	China	
20.	NPPA means-			
	a. National pharmaceutical pricing authority	b.	National pharmacy product act	
	c. New pharmacy product advertisement	d.	National public protection act	

2

USTM/COE/R-01

PART-B: Descriptive

Time: 2 hrs. 30 min. Marks: 35					
[Answer any seven (7) questions]					
1.	Explain in details about the phases of clinical trials.	5			
2.	What is a purple book. Mention the purposes of a purple book.	1+4=5			
3.	Explain NDA and classify the drugs in NDA.	1+4=5			
4.	What a short note on CTD. What are the various modules of CTD.	2+3=5			
5.	Write about IRB/IEC mentioning its composition and procedures.	2+3=5			
6.	Write short notes on: a. CDSCO b. DTAB	2.5+2.5 =5			
7.	Explain about "Concept of generics".	5			
8.	Write about a) Narcotic and psychotropic Act. b) Consumer Protection act.	2.5+2.5 =5			
9.	Write about the rules related to export of drugs from India.	5			

PART-C: Long type questions

[Answer any two (2) questions]

Write and explain in details about the stages of drug discovery.
 Write short notes on:

 Innovator drugs
 Orange book

3. Explain in details about the steps involved in developing clinical trial protocols.

= = *** = =